Wednesday - CBL - drugs

Question 1

Vincristine

Answer 1

Cell Cycle Specific -Metaphase MT inhibitor, Vincristine binds to tubulin dimers, inhibiting assembly of microtubule structures and arresting mitosis in metaphase. IV treatment. Cytostatic.

Question 2

Doxorubicin

Answer 2

CCNS. Intercalating agent (inhibits Topo II and causes DNA breaks). IV treatment.

Question 3

Ara-C

Answer 3

Pyrimidine imitator, cytosine analog, inhibits DNA polymerase. S phase-specific. IV treatment.

Question 4

Lenalidomide

Answer 4

• decreases osteoclast activity
• most potent anti-TNF-alpha (causes immunosuppression)
• anti VEGF
• interferes with growth signaling

Question 5

cyclophosphamide

Answer 5

Alkylating agent, non-cell cycle specific. IV treatment. Myeloid leukemias have been shown to be linked to alkylating agents.

Question 6

6-mercaptopurine

Answer 6

Blocks purine synthesis. “Pseudofeedback inhibition” of PNP and PRPP. (DNA synthesis inhibitor). Oral treatment

Question 7

Methotrexate

Answer 7

dihydrofolate reductase inhibitor, limits purine synthesis→ limits DNA synthesis, s phase specific. Oral treatment. `

Question 8

Bortezomib

Answer 8

Proteosome inhibitor, causes increase in ubiquitin

Question 9

Retuximab

Answer 9

Binds CD20 on B cells, improves ability of NK cells to attack those B cells

Question 10

Entecavir

Answer 10

Nucleoside analog, inhibits reverse transcription, DNA replication and transcription.

Question 11

Melphalan

Answer 11

Alkylation of DNA nucleotide guanine, DNA linkage

Question 12

Thalidomide

Answer 12

inhibits NF-KB leading to inhibition of TNF-a, IL-6, IL-12 production. Modulates production IFN gamma